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The aim of the study was to evaluate the role of epidoxorubicin plus paclitaxel combination (ET) vs single agent paclitaxel (T), as
second-line chemotherapy treatment in advanced ovarian cancer patients in early progression within 12 months after platinum-based
chemotherapy. From October 1994 up to June 1999, 234 patients from 34 Italian hospitals were randomised to receive: (A)
epidoxorubicin (E) 80mgm
 2 þ paclitaxel (T) 175mgm
 2 (3h infusion), every 21 days for 4–6 cycles. (B) Paclitaxel 175mgm
 2
(3h infusion) every 21 days for 4–6 cycles. Evaluable for survival analysis were 106 and 106 patients in ET and T arm, respectively.
Platinum-based monochemotherapy was the first-line treatment in 43% patients, while polichemotherapy containing anthracyclines
was the preferred first-line therapy in 22% patients. The median time from the end of first-line therapy to randomisation was 3
months. Treatment was completed in 87 and 85% of T and ET arm, respectively. Haematological toxicity was significantly more
common in ET group (ECOG grade 3–4 neutropenia: 37.4% in ET vs 18.2% in T arm). Neuropathies were similar in both arms
(sensory: ECOG grade 2–3: 12.1% in ET vs 14.7% in T arm, motor: 6.1% in ET vs 5.3% in T arm). Objective response was achieved in
37.4% of patients in ET group and in 46.9% of patients in T arm. At a median follow-up of time of 48 months, a total of 180 patients
progressed and 163 patients died. Survival analysis showed no difference between ET and T (median time to progression: 6 months
for both regimens, median survival: 12 and 14 months for ET and T, respectively; hazard ratio for mortality of ET vs T: 1.17 (95% CI
0.86–1.59; P¼0.33). The ET regimen does not seem to be more effective than T in refractory advanced ovarian cancer patients in
early progression after platinum-based chemotherapy. Despite an acceptable response rate, the control of disease progression
remains poor.
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Ovarian cancer, fifth cause of cancer death in European
women, is the most common cause of death among women
with gynaecological malignancies. An estimated 25200 new cases
of ovarian cancer are diagnosed annually in the US and
about 14500 women die every year (Landis et al, 1999). Ovarian
cancer is often diagnosed in advanced phase (stage III and IV) and
the prognosis is generally poor despite activity shown by
chemotherapy agents. Although up to 80% of cases achieve an
objective response with platinum-containing regimens, about 22%
of patients progress while receiving initial platinum-based
treatment and are defined refractory to chemotherapy (Kavanagh
et al, 1995), 40% of patients generally relapse or progress within 12
months and 20% after 12 months from the end of first-line
chemotherapy (Ozols and Young, 1991; Thigpen, 1999). The
probability of a second response increases with the relapse-free
period (Seltzer et al, 1985; Gore et al, 1990; Markman et al, 1991;
Weiss et al, 1991; Zanaboni et al, 1991; Eisenhauer et al, 1997;
Cantu ` et al, 2002).
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lFor these patients, second-line treatment include drugs that are
noncrossresistant with platinum compounds including ifosfamide,
anthracyclines at standard or high dose (Markman et al, 1992;
Thigpen et al, 1993; Vermorken et al, 1994; Vermorken and
Pecorelli, 1996) and, more recently, taxanes.
In a review analysis, Vermorken et al (1999) showed that 25 out
of 75 (33%) chemotherapy patients from several trials achieved an
objective response to single agent doxorubicin. The results of
single agent epirubicin appear to be better in prior platinum-
exposed patients. Paclitaxel, an antimitotic agent derived from
bark of Pacific Yew tree Taxus brevifolia (Schiff et al, 1979),
proved to be active in relapsed and platinum-resistant ovarian
cancer (McGuire et al, 1989; Einzig et al, 1992; Trimble et al, 1993;
Kohn et al, 1994; Gore et al, 1995) and was well tolerated by most
patients: significant side effects other than alopecia were
uncommon (Seidman et al, 1996). Moreover, preliminary data in
advanced breast cancer patients seemed to suggest that the
combination of paclitaxel plus doxorubicin might have a potential
interaction in efficacy (Gianni et al, 1994). In absence of sound
data to support the use of paclitaxel as single agent or in
combination with anthracyclines in the second-line treatment of
ovarian cancer, we set up a randomised multicenter phase III trial.
This trial aimed at evaluating the efficacy and feasibility of
paclitaxel as single agent compared to a combination including
paclitaxel and epidoxorubicin, administered as second-line che-
motherapy for epithelial ovarian cancer patients progressing
within 1 year from the end of first-line platinum-based
chemotherapy. Patients exposed to largely sub-maximally cumu-
lative doses of anthracyclines in first-line platinum-based che-
motherapies were deemed still eligible for this study.
MATERIALS AND METHODS
Design
The study was run as parallel trial, adopting a randomisation ratio
between arms of 1:1. Randomisation was performed calling the
coordinating centre located at the Istituto di Ricerche Farm-
acologiche ‘Mario Negri’, Milan. A stratification was adopted
considering centre and response achieved after first-line che-
motherapy, in terms of progression during treatment (refractory
patients), partial or stable disease, relapse within 12 months.
Ethics committee
The study protocol was revised and accepted by local ethical
committees; informed consent was obtained before randomisation
from all patients in accordance with national legislation following
the principles enunciated in the Declaration of Helsinki (Vastag,
2000).
Eligibility
Patients with histological proven ovarian carcinoma platinum
resistant, relapsed or progressed within 12 months since the end of
a first-line therapy containing cisplatin or carboplatin, were
eligible for the study. Further eligibility criteria included:
measurable disease, World Health Organization (WHO) perfor-
mance status p2; adequate bone marrow function (absolute
granulocyte count X2000mm
 3, platelet count X100000mm
 3);
adequate renal, hepatic and cardiac functions. Patients were
considered not eligible if they had received more than one
previous chemotherapy line or if the first-line chemotherapy
contained taxanes. Prior anticancer treatment with anthracyclines
was allowed provided patients had not received cumulative doses
in excess of 300 or 360mgm
 2 for doxorubicin or epidoxorubicin,
respectively.
Chemotherapy regimen
Patients were randomised to receive T or ET, intravenously, at 3-
week intervals, as soon as possible after randomisation.
Paclitaxel was given 175mgm
 2 over 3h infusion. Premedica-
tion given to reduce the risk of paclitaxel hypersensitivity,
was as follows: Desamethasone 40mg, given as 20mg at 12 and
6h before paclitaxel, 300mg of Cimetidine and 10mg of
Chlorpheniramine intravenously, 30min before the treatment.
Epidoxorubicin 80mgm
 2 intravenously was administered as a
bolus followed by paclitaxel 175mgm
 2 over 3h infusion, as
already described. Each patient had to receive a minimum of four
cycles of chemotherapy but patients with progressing disease at the
first 2 month evaluation were considered off study and the
assigned treatment was interrupted. After completion of four
cycles, two additional cycles of protocol treatment were proposed
to all patients not showing disease progression. Patients were
allowed to receive any third-line chemotherapy at investigators’
discretion.
Treatment modifications
Toxiciy was graded on a scale of 1–4 according to the WHO
criteria. If, at the time of scheduled retreatment, white blood cell
count was X1500mm
 3 and platelets count X100000mm
 3,
chemotherapy was given without reductions or delays, otherwise it
was delayed by 1 week or reduced according to type and grade of
toxicity. The following indications of toxicity led to dose
modification: (a) nadir neutrophil count between 500 and
1000mm
 3 or nadir platelet count between 50000 and
100000mm
 3: dose level – 1 (see below); (b) nadir neutrophil
count less than 500mm
 3 or nadir platelet count less than
50000mm
 3: dose level – 2 (see below); (c) any nonhaematologic
grade 2 toxicity: dose level – 1; (d) any nonhaematologic toxicity
more than grade 2: treatment to be interrupted until the adverse
effects resolve. Dose levels were as follows for paclitaxel and
epidoxorubicin, respectively. Initial dose, 175 and 80mgm
 2; level
– 1, 135 and 65mgm
 2 ; level – 2 110 and 50mgm
 2.
Assessment of response
Response to study drug, assessed using ECOG criteria (Miller
et al, 1981), was based on objective tumour evaluation every two
cycles.
A complete response (CR) was defined as complete
disappearance of all measurable and assessable lesions no new
lesions and no related symptoms. A partial response (PR)
was documented in patients with a X50% decrease in the sum
of the products of bidimensional perpendicular diameters of all
measurable lesions. Progressive disease (PD) was said to occur in
patients with a X50% increase in the sum of the products of
bidimensionally measured lesions over the smallest sum obtained
at best response, or clear worsening of any assessable disease, or
failure to return to evaluation because of death or deteriorating
condition, or the appearance of any new lesion or site. Patients
were classified as having stable disease if they did not qualify for
CR, PR or PD.
Follow-up programme
Once patients were off the protocol treatments, they were
monitored for assessment of disease status and long-term toxicities
every 3 months for 2 years and every 6 months thereafter. Follow-
up procedures comprised clinical examination, blood chemistry
and CA 125 (optional) estimation. ECG and echocardiography for
cardiac function assessment were scheduled at 6 and 12 months
and yearly thereafter; routine computed tomography, abdomen
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lechography or chest radiography were not required but were
requested if biomarkers rose or symptoms developed.
Analysis
The primary outcome measure was overall survival; secondary
outcomes were progression-free survival and response to treat-
ment.
The trial was designed to have an 80% power to detect a 33%
relative reduction in mortality (i.e. increasing median overall
survival of about 6 months), corresponding to a hazard ratio of
0.67 with a two-sided a of 0.05. We anticipated that 230 patients
would have to be recruited to the trial to meet these specifications.
The final analysis was designated to occur when at least 85% of the
eligible patients experienced either progression or death.
We compared Kaplan–Meier curves for overall survival and
progression-free survival using the Mantel–Cox version of the log-
rank test (Kaplan and Meier, 1958; Makuch and Simon, 1982). The
Cox proportional hazards regression model (Parmar and Machin,
1995) was also used for progression-free and overall survival to
estimate the treatment relative hazards (HRs), while adjusting for
multiple prognostic factors.
Response to chemotherapy treatments was compared with
Mantel–Haenszel w
2 test for trend.
Overall survival was defined as the time from randomisation to
death from any cause; patients known to be still alive at the time of
the analysis were censored at the time of their last follow-up.
Progression-free survival was defined as the time from randomisa-
tion to first appearance of PD or death from any cause; patients
known to be alive and without PD at the time of analysis were
censored at the time of their last follow-up. Absolute benefits at
specific time points were calculated using the Kaplan–Meier
estimate of survival in the control group at the time point (control
survival) and hazard ratio with the expression: absolute bene-
fit¼exp (hazard ratio   log (control survival)) control survival.
This approach was also adopted for the end point of progression-
free survival. Although this approach implicitly assumes propor-
tional hazards, it is preferable to reading differences between
Kaplan–Meier curves at individual time points. Differences in
medians were calculated in a similar way but using the expression
difference in medians¼(control median/hazard ratio) control
median. This approach assumes approximately exponentially
distributed survival times. The relative benefits of platinum-based
chemotherapy on survival were assessed in an exploratory manner
in subgroups defined by prior use of anthracyclines and refractory
status. To test for differences in the relative size of effect in
different subgroups, we used a w
2 test for interaction, or, when
appropriate, a w
2 test for trend.
All analyses were performed on an intention-to-treat basis on
eligible patients except for the analyses of toxicity. The latter
analyses were restricted to all patients who received at least one
cycle of allocated treatment. All P-values are two-sided. Analyses
were carried out using SAS System Version 8.20. No interim
analysis was planned or performed.
RESULTS
Accrual
Between October 1994 and June 1999, 234 patients were enrolled
into the trial from 34 Italian centres. Final survival analysis was
performed on 212 patients, as there were 11 major violations of the
protocol (six patients were given paclitaxel in first-line therapy,
two had more then one first-line therapy, two patients had a
disease-free interval greater than 12 months and one patient had
cardiac impairment) and 11 further patients were early lost to
follow-up. Figure 1 reports the flow chart of the progress of
patients through the trial.
Patient characteristics
Pretreatment characteristics were well balanced within randomised
groups as listed in Table 1: median age was about 60 years,
platinum-based monochemotherapy was the first-line treatment in
43% of patients. Polichemotherapy containing anthracyclines was
the preferred first-line therapy in 22% of patients. Progression
during first-line chemotherapy was observed in 32% of cases.
Median time from the end of first-line chemotherapy was 3
months.
Compliance and toxicity
In all, 87 and 85% of the patients completed the scheduled therapy
in T and ET, respectively. However, modification of dosage or time
accounted for 9 and 41% of cases (Po0.001), and interruption due
Five excluded, 
eligibility violation
Three early lost 
to follow-up
78 died
30 still in follow-up
after 2 years
114 allocated to T
Six excluded, 
eligibility violation
Eight early lost 
to follow-up
85 died
18 still in follow-up
after 2years
120 allocated to ET
234 randomised 
patients
Figure 1 Flow chart of the progress of patients through the trial
Table 1 Patient characteristics
TE T
Evaluable patients 106 106
Age – Median (min–max) 59 (24–78) 60 (28–77)
Performance status
0–1 99 (93.4%) 97 (91.5%)
2–3 7 (6.6%) 9 (8.5%)
Previous treatment
Monochemotherapy 48 (45.3%) 43 (40.6%)
Polichemotherapy no anthracyclines 29 (27.4%) 31 (29.2%)
Polichemotherapy with
anthracyclines
23 (21.7%) 24 (22.6%)
Unknown 6 (5.7%) 8 (7.5%)
Months from the end of first-line
chemotherapy
Median (min–max) 3 (0–12) 3 (0–12)
Time of occurrence of progression
During first line chemotherapy 33 (31.1%) 39 (36.8%)
Within 6 months from the end of
first-line chemotherapy
46 (43.4%) 37 (34.9%)
6–12 months from the end of first-
line chemotherapy
26 (24.5%) 29 (27.4%)
Unknown 1 (0.9%) 1 (0.9%)
T¼paclitaxel; ET¼ epidoxorubicin plus paclitaxel. Bold values indicate the number
of patients (n).
Epidoxorubicin plus paclitaxel in advanced ovarian cancer
A Buda et al
2114
British Journal of Cancer (2004) 90(11), 2112–2117 & 2004 Cancer Research UK
C
l
i
n
i
c
a
lto toxicity were 9 and 13% (P¼NS), respectively. Four percent of
patients in both arms refused therapy after randomisation. A
median number of six courses, with an interquartile range from 4
to 6, was given to T group and a median number of five courses,
with an interquartile range from 3 to 6, was given to ET group.
Table 2 shows the proportion of patients with toxic effects
observed during treatment. Levels of haematological toxicity were
quite different across the arms. The ET was associated with higher
rates of grade 3 or 4 haematological toxicity: leuckopenia and
neutropenia. Other nonhaematological toxicities occurred as
expected and the toxicity profiles of the two groups were similar.
Response
Response evaluation results are shown in Table 3. Data were
available in 181 patients. The overall response rate was 46.9% in T
(CR: 20.2%; PR: 26.7%) and 37.4% in ET (CR: 15.4%; PR: 22.0%),
while PD was observed in 27.8 and 36.3% of patients, respectively
(Mantel–Haenszel w
2 test for trend: 1.89, P¼0.17). The overall
high rate of overall response was largely due to the patients
progressing after 6 months since the end of first-line chemother-
apy. In fact, a subset analysis in this population showed an overall
response rate as high as 60% in T and 48% in ET.
Overall survival
At a median follow-up of 48 months, 163 (76.9%) patients have
died. Comparing the survival curves (Figure 2), the hazard ratio of
1.17 (95% CI: 0.86–1.59; P¼0.33) translates into an absolute
difference in 1-year survival of 6% (95% CI for difference:  5t o
16%) in favour of single agent paclitaxel, from 50 to 56%. In terms
of median survival, the hazard ratio translates into a difference of 2
months (95% CI for difference: -2 to 5 months) with a median
survival of 14 months on the paclitaxel alone arm and 12 months
on the paclitaxel plus epidoxorubicin chemotherapy arm.
Progression-free survival
A total of 180 (84.9%) patients have progressed or died.
Progression-free interval curves are shown in Figure 3. The hazard
ratio of 1.00 (95% CI: 0.75–1.35; P¼0.96) translates into an
absolute difference in 6-months survival of 0% (95% CI for
difference:  10 to 10%). In terms of median survival, the hazard
ratio translates into a difference of 0 months (95% CI for
difference:  2 to 2 months) with a median survival of 6 months
on both chemotherapy arms.
Effects in different subgroups
We found no definite evidence that paclitaxel plus epidoxorubicin
was more or less effective than paclitaxel alone in any subgroup for
either overall survival or progression-free survival (Table 4).
However, a statistically borderline test for interaction suggests that
previous exposure to anthracyclines-based first-line chemotherapy
might interact in the relative performance of the two regimens,
favouring ET combination.
Table 2 Toxicity evaluation
TE T P
Evaluable patients 99 99
Haematological grade III–IV
Leucopenia 9 (9.1%) 19 (19.2%) 0.06
Neutropenia 18 (18.2%) 37 (37.4%) 0.01
PLT 1 (1.0%) 1 (1.0%) 0.58
HB 5 (5.0%) 3 (3.0%) 0.10
Non haematological
Neuropathy (II–III)
- Sensorial 14 (14.1%) 12 (12.1%) 0.32
- Motor 5 (5.0%) 6 (6.0%) 0.83
Cardiac (II–III) 2 (2.0%) 1 (1.0%) 0.41
Nausea, vomiting (III–IV) 6 (6.0%) 11 (11.1%) 0.36
Alopecia (III–IV) 68 (68.7%) 61 (61.6%) 0.24
T ¼ paclitaxel; ET ¼ epidoxorubicin plus paclitaxel. Bold values indicate the number
of patients (n).
Table 3 Response evaluation
TE T
Evaluable patients 90 91
CR 18 (20.2%) 14 (15.4%)
PR 24 (26.7%) 20 (22.0%)
SD 23 (25.6%) 24 (26.4%)
PD 25 (27.8%) 33 (36.3%)
Median duration of response (mos) (min–max) 8 (1–49) 11 (1–53)
w
2 test for trend : 1.89, P¼0.17. T ¼ paclitaxel; ET ¼ epidoxorubicin plus paclitaxel;
CR ¼ complete response; PR ¼ partial response; SD ¼ stable disease; PD ¼
progressive disease. Bold values indicate the number of patients (n).
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lDISCUSSION
Salvage therapies in relapsed epithelial ovarian cancer are rarely
curative and usually result in low response rates with small impact
on survival. The current management of patients with recurrent
ovarian carcinoma is based on the results of the initial
chemotherapy. In the early 1990s, paclitaxel became the major
second-line treatment for ovarian cancer and soon after gained the
role of standard first-line treatment in combination with platinum
compounds (Thigpen et al, 1994; Kavanagh et al, 1995). More
recently, the negative results of two large-scale clinical trials
(Muggia et al, 2000; ICON3 group, 2002) have challenged the
general consensus on paclitaxel as a first-line therapeutic
approach. In accordance with these new evidences, for example,
the UK National Institute for Clinical Excellence (NICE) has
revised its guidance on the use of paclitaxel in the treatment of
ovarian cancer in January 2003 (NICE, 2003) and recommended
that paclitaxel in combination with platinum-based compound or
platinum-based therapy alone are offered as alternatives for first-
line chemotherapy. This means that the patients who were eligible
for our study still possibly represent a significant subset of the
ovarian cancer patients currently referring to oncologic out-
patient’s departments. The most important aspect emerging from
this study, which, to our knowledge, is one of the largest phase III
randomised trials ever performed in recurrent ovarian cancer, is
that the combination of two noncrossresistant drugs failed to
achieve better results and was associated to an higher toxicity than
the single agent paclitaxel in the management of advanced ovarian
cancer patients in early progression after platinum-based che-
motherapy. Our data can be compared with the results emerged
from the study of Bolis et al (1999). In this multicenter phase III
randomized trial, combination of paclitaxel plus epidoxorubicin
gave a higher response rate than single agent paclitaxel. In 81
evaluable patients, the overall response rates was 17% in paclitaxel
arm and 34% in the combination arm but, in keeping with our
findings, toxicity was higher in combination therapy, duration of
response was limited to a few months, and the 2-year survival was
similar between the two groups. Typically, response rates to
second-line chemotherapy in platinum-resistant recurrent ovarian
cancer is modest although overall response rates up to 40% have
been reported in the literature (Salom et al, 2002). The high
proportion of patients achieving an objective response in our study
is mainly due to the fact than about a quarter of our study
population had a disease-free interval greater than 6 months (but
less than 12 months), while most of the series of platinum-resistant
patients included only patients recurring within 6 months.
However, comparing response rates across studies makes clear
that a strong relationship between response and survival is not to
be expected in this setting and therefore clinical outcome measures
related to survival or quality of life should be preferred for efficacy
assessment.
The findings of this trial indicate that the combination of
paclitaxel plus epidoxorubicin does not seem to be more effective
than single agent paclitaxel in patients in early progression after
first-line platinum-based treatment. In subset analyses, the
appearance of a statistically borderline test for interaction
suggesting a different performance on survival of ET when
compared with T in patients who were given anthracyclines in
first-line therapy came unexpected. We deemed this finding devoid
of a real clinical value apart from confirming that anthracyclines
resistance did not develop in these patients.
If the combination of common cytotoxic drugs does not
seem to improve survival in patients with refractory ovarian
cancer, further studies are necessary to address the open
questions regarding the best second-line therapy in the recurrent
disease setting. There is now evidence suggesting that drug
resistance is partly a result of defects in the apoptotic pathway
that, after previous chemotherapy, can determine selection of
tumour cells, more resistant to subsequent agents (Cannistra,
2002). Also, the role of paclitaxel has to be further defined: recent
data suggest that a possible role of paclitaxel may be in cisplatin-
resistant clones of cells that overexpress mutated p53
protein (Smith-Sorensen et al, 1998; Judson et al, 1999). Large
comparative trials of second-line treatment should be planned to
test the available new active agents, which have different
mechanisms of action and potentially limited serious toxicity,
while offering the best framework to improve our knowledge of
predictive factors.
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Table 4 Effect of chemotherapy in different subgroups
PFS OS
Effect of ET vs T HR 95% CI HR 95% CI
Stratification factors
Previous use of anthracyclines
No 1.05 0.75–1.46 1.38 0.97–1.96
Yes 0.90 0.48–1.68 0.68 0.34–1.34
w
2 test for interaction P¼0.857 P¼0.060
Refractory status
No 1.03 0.73–1.47 1.08 0.74–1.58
Yes 0.92 0.54–1.56 1.38 0.80–2.37
w
2 test for interaction P¼0.718 P¼0.403
Treatment relative hazards (HRs) HRs more than 1 are in favour of T, HRs less than
1 are in favour of ET. PFS¼ progression-free survival; OS¼ overall survival; HR¼
treatment relative hazards; 95% CI¼ 95% confidence interval; ET¼ epidoxorubin
plus paclitaxel; T¼ paclitaxel.
Epidoxorubicin plus paclitaxel in advanced ovarian cancer
A Buda et al
2116
British Journal of Cancer (2004) 90(11), 2112–2117 & 2004 Cancer Research UK
C
l
i
n
i
c
a
lREFERENCES
Bolis G, Parazzini F, Scarfone G, Villa A, Amoroso M, Rabaiotti E, Polatti A,
Reina S, Piroetti E (1999) Paclitaxel vs epidoxorubicin plus paclitaxel as
second-line therapy for platinum-refractory and resistant ovarian cancer.
Gynecol Oncol 72: 60–64
Cannistra S (2002) Is there a ‘best’ choice of second-line agent in the
treatment of recurrent, potentially platinum-sensitive ovarian cancer? J
Clin Oncol 20: 1158–1160
Cantu ` MG, Buda A, Parma G, Rossi R, Floriani I, Bonazzi C, Dell’Anna T,
Torri V Colombo N (2002) Randomized controlled trial of single-agent
paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in
patients with recurrent ovarian cancer who responded to first-line
platinum-based regimens. J Clin Oncol 20: 1232–1237
Einzig AI, Wiernik PH, Sasloff J, Runowicz CD, Goldberg GL (1992) Phase
II and long-term follow-up of patients treated with Paclitaxel for
advanced ovarian adenocarcinoma. J Clin Oncol 10: 1748–1753
Eisenhauer EA, Vermorken JB, van Glabbeke M (1997) Predictors response
to subsequent chemotherapy in platinum pre-treated ovarian cancer: a
multivariate analysis of 704 patients. Ann Oncol 8: 963–968
Gianni L, Straneo M, Capri G, Villani F, Munzone E, Bonadonna G (1994)
Optimal dose and sequence finding study of paclitaxel (p) by 3h infusion
combined with bolus doxorubicin (d) in untreated metastatic breast
cancer patients (pts). Proc Am Soc Clin Oncol 74: 97
Gore ME, Fryatt I, Wiltshaw E, Dawson T (1990) Treatment of relapsed
carcinoma of the ovary with cisplatin or carboplatin following initial
treatment with these compounds. Gynecol Oncol 36: 707–711
Gore ME, Levy V, Rustin G, Perren T, Calvert AH, Earl H, Thompson JM
(1995) Paclitaxel (Paclitaxel) in relapsed and refractory ovarian cancer:
the UK and Eire experience. Br J Cancer 72: 1016–1019
Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete
observations. J Am Stat Assoc 53: 457–481
Kavanagh J, Tresukosol D, Edwards C, Freedman R, Gonzales de Leon C,
Fishman A, Mante R, Hord M, Kudelka A (1995) Carboplatin reinduction
after taxane in patients with platinum-refractory epithelial ovarian
cancer. J Clin Oncol 13: 1584–1588
Kohn EC, Sarosy G, Bicher A, Link C, Christian M, Steinberg SM,
Rothenberg M, Adamo DO, Davis P, Ognibene FP (1994) Dose-intense
Paclitaxel: response rate in patients with platinum-resistant recurrent
ovarian cancer. J Natl Cancer Inst 86: 18–24
Judson PL, Watson JM, Gehrig PA, Fowler Jr WC, Haskill JS (1999)
Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant
ovarian cancer cell lines: possible explanation for failure of combination
therapy. Cancer Res. 59: 2425–2432
Landis SH, Murray T, Bolden S, Wingo PA (1999) Cancer statistics, 1999.
CA Cancer J Clin 49: 8–31
Makuch RW, Simon RM (1982) Sample size requirements for comparing
time-to-failure among k treatment groups. J Chron Dis 35: 861–867
Markman M, Hakes T, Reichman B, Lewis Jr JL, Rubin S, Jones W,
Almadrones L, Pizzuto F, Hoskins W (1992) Ifosfamide and mesna in
previously treated advanced epithelial ovarian cancer: activity in
platinum-resistant disease. J Clin Oncol 10: 243–248
Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, Jones
W, Almadrones L, Lewis Jr JL (1991) Second-line platinum therapy in
patients with ovarian cancer previously treated with cisplatin. J Clin
Oncol 9: 389–393
McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS,
Armstrong DK, Donehower RC (1989) Taxol: a unique anti-neoplastic
agent with significant activity in advanced ovarian epithelial neoplasms.
Ann Intern Med 111: 273–279
Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of
cancer treatment. Cancer 47: 207–214
Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, Alvarez
RD, Kucera PR, Small JM (2000) Phase III randomized study of cisplatin
versus paclitaxel versus cisplatin and paclitaxel in patients with
suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology
Group Study. J Clin Oncol 18: 106–115
NICE (2003) National Institute for Clinical Excellence Technology Appraisal
Guidance No 55. London: NICE www.nice.org.uk
Ozols RF, Young RC (1991) Chemotherapy of ovarian cancer. Semin Oncol
3: 222–232
Parmar MKB, Machin D (1995) Survival Analysis: a Practical Approach.
Chichester: John Wiley
Salom E, Almeida Z, Mirhashemi R (2002) Management of recurrent
ovarian cancer: evidence-based decisions. Curr Opin Oncol 14: 519–527
Schiff PB, Fant J, Horwitz SB (1979) Promotion of microtubule assembly in
vitro by Paclitaxel. Nature 11: 716
Seidman AD, Hochhauser D, Gollub M, Edelman B, Yao TJ, Hudis CA,
Francis P, Fennelly D, Gilewski TA, Moynahan ME, Currie V, Baselga J,
Tong W, O’Donaghue M, Salvaggio R, Auguste L, Spriggs D, Norton L
(1996) Ninety-six hour Paclitaxel infusion after progression during short
taxane exposure: a phase II pharmacokinetic and pharmacodynamic
study in metastatic breast cancer. J Clin Oncol 14: 1877–1884
Seltzer V, Vogl S, Kaplan B (1985) Recurrent ovarian carcinoma: treatment
utilizing combination chemotherapy including cisdiamminedichloropla-
tinum in patients previously responding to this agent. Gynecol Oncol 21:
167–176
Smith-Sorensen B, Kaern J, Holm R, Dorum A, Trope C, Borresen-Dale AL
(1998) Therapy effect of either Paclitaxel or cyclophosphamide
combination treatment in patients with epithelial ovarian cancer and
relation to TP53 gene status. Br J Cancer 78: 375–381
The International Collaborative Ovarian Cancer Neoplasm (ICON) Group
(2002) Paclitaxel plus carboplatin versus standard chemotherapy with
either single-agent carboplatin or cyclophosphamide, doxorubicin, and
cisplatin in women with ovarian cancer: the ICON3 randomised trial.
Lancet 360: 505–515
Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ (1994) Phase II trial
of Paclitaxel in patients with progressive ovarian carcinoma after
platinum-based chemotherapy: a Gynecologic Oncology Group study.
J Clin Oncol 12: 1748–1753
Thigpen JT, Vance RB, Khansur T (1993) Second-line chemotherapy for
recurrent carcinoma of the ovary. Cancer 71: 1559–1564
Thigpen T (1999) Second-Line Therapy for Ovarian Carcinoma: General
Concepts, ASCO Educational book: Atlanta, GA: American Society of
Clinical Oncology 564–566
Trimble EL, Adams JD, Vena D, Hawkins MJ, Friedman MA, Fisherman JS,
Christian MC, Canetta R, Onetto N, Hayn R (1993) Paclitaxel for
platinum-refractory ovarian cancer: results from the first 1,000 patients
registered to National Cancer Institute Treatment Referral Center 9103.
J Clin Oncol 11: 2405–2410
Vastag B (2000) Helsinki discord? A Controversial Declaration. JAMA 284:
2983–2985
Vermorken JB, Bolis G, van Rijswijk RE, Kobierska A, Chevallier B, van der
Burg ME, Zanaboni F, Lentz MA, Burger CW, Kenemans P, Pinedo HM
(1994) High-dose intensity regimens with epirubicin in ovarian cancer.
Semin Oncol 21: 17–22
Vermorken JB, Harper PG, Buyse M (1999) The role of anthracyclines in
epithelial ovarian cancer. Ann Oncol 10: 43–50
Vermorken JB, Pecorelli S (1996) Clinical trials in patients with epithelial
ovarian cancer: past, present and future. Eur J Surg Oncol 22: 455–466
Weiss G, Geen S, Albert DS, Thigpen JT, Hines HE, Hanson K, Pierce HI,
Baker LH, Goodwin JW (1991) Second-line treatment of advanced
measurable ovarian cancer with iproplatin: a Southwest Oncology Group
Study. Eur J Cancer 27: 135–138
Zanaboni F, Scarfone G, Presti M, Maggi R, Borello C, Bolis G
(1991) Salvage chemotherapy for ovarian cancer recurrence: weekly
cisplatin in combination with epirubicin or etoposide. Gynecol Oncol 43:
24–28
Epidoxorubicin plus paclitaxel in advanced ovarian cancer
A Buda et al
2117
British Journal of Cancer (2004) 90(11), 2112–2117 & 2004 Cancer Research UK
C
l
i
n
i
c
a
l